1. Introduction {#s0005}
===============

A burn is defined as damage to the skin caused by excessive heat or caustic chemicals. The most common burn injuries result from exposure to heat and chemicals ([@b0235]). Burns is a prevalent and burdensome critical care problem ([@b0165]). The depth of a burn wound and/or its healing potential are the most important factors of the therapeutic management and the residual morbidity or scarring ([@b0135]). Wound healing is an active and dynamic process that begins from the moment of injury. Any delay in the initiation of the response to injury can prolong the healing process ([@b0065]).

Microorganisms that cause burn wound infections have changed over years related to changes made in the treatment of burn patients. Infection is a major complication of burn injury and is responsible for 50--75% of hospital deaths ([@b0045]). Many of the antimicrobial agents are designed to be used prophylactically to prevent infection developing, while others are designed to kill the microbial cells that are proliferating within the burn when an infection has developed ([@b0035]). Election of topical antimicrobial therapy should be based on the agent's ability to inhibit the microorganisms recovered from burn wound surveillance cultures ([@b0005]). Fusidic acid (FA) is an antibiotic agent derived from the fungus *Fusidium coccineum* ([@b0105]), belongs to the class of steroids, but has no corticosteroid (anti-inflammatory or immunosuppressive properties) effects. Nowadays, it is available in many formulations for oral (tablet and suspension), intravenous, and topical (cream and ointment) administration. For skin infections treatments, many doctors prescribe topical fusidic acid. The most frequent indications are boils, anthrax or carbuncle, erythema, cellulitis, folliculitis, acne, paronychia, hidradenitis, and wound infections due to burns and impetigo ([@b0015], [@b0020]).

A microemulsion is defined as a dispersion consisting of oil, surfactant, co-surfactant and aqueous phase, which is a thermodynamically stable liquid solution. They are homogenous dispersions of water in oil (w/o) or oil in water (o/w) droplets stabilized by surfactants ([@b0075], [@b0255]). From preparation and sterilization, microemulsions are relatively simple and inexpensive systems ([@b0095]). These formulations are also used to prepare poorly water-soluble drugs because their structure allows the solubilization of lipophilic drugs in the oil phase ([@b0250]). The administration of microemulsions as a solution onto the skin can be challenging due to its low viscosity. To optimize the microemulsion as a dermal formulation, different hydrogels such as chitosan, xanthan gum, carbomer, and carrageenan have been studied to increase the viscosity of formulations ([@b0060]). To minimize this effect the thickening agent can be introduced into the system in order to transform it from liquid to semisolid state ([@b0050]). The addition of gelling components into microemulsions produces microemulsion-based hydrogels, which are easier to apply to the skin compared to runny liquid formulations ([@b0070]). The stable microemulsion based hydrogel has good permeation ability and suitable viscosity for the topical delivery, which provided longer contact with skin ([@b0060]).

The aim of this work was to develop novel FA loaded microemulsion formulations for burn healing treatment. For this purpose, characterization, drug release, stability, anti-inflammatory activity and *in vivo* of the formulations were investigated.

2. Materıals and methods {#s0010}
========================

2.1. Materials {#s0015}
--------------

FA was a kind gift from Berko İlaç, Turkey. Ethyl oleate (EO) was purchased from Sigma-Aldrich, UK. Chitosan oligosaccharide lactate (COL) was obtained from Sigma-Aldrich, USA. Tween 80 (Polysorbate 80) and Nutrient Agar (1.05450) were purchased from Merck, Germany. Acetonitrile (Sigma, Germany) was used for high pressure liquid chromatography (HPLC). Ultrapure water was obtained from Direct-Q® Water Purification System, Germany. Spectra/por dialysis membrane was purchased from Spectrum. Fluid Thioglycollate Medium (CM0173) and Soy Bean Casein Medium were obtained from Oxoid, Thermo-Fisher Scientific. Mueller-Hinton II Agar (70191) was purchased from Sigma-Aldrich Co. Type cultures of bacteria were purchased from ATCC, USA. Dulbecco's modified Eagle's medium (DMEM) was obtained from Gibco, USA, MTT was purchased from AppliChem, Germany. Isopropanol, sulfanilamide and N-(1-naphthyl)ethylenediamine dihydrochloride were purchased from Sigma--Aldrich, USA, phosphoric acid from Mettler, Switzerland.

2.2. Preparation of microemulsion formulation {#s0020}
---------------------------------------------

The existence range of microemulsions was understood by using pseudo-ternary phase diagrams. Titration method was used to obtain microemulsions. A series of oil and surfactant/co-surfactant mixtures (1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, and 9:1 at weight ratios) with ultrapure water at 25 ± 1 °C were titrated. After that, microemulsions were determined by visually examining the mixtures. The HLB value of formulation was determined as 15. A software program was used to construct the phase diagrams. All preparations were repeated at least four times. Microemulsion formulation was developed in accordance with the microemulsion area in the phase diagrams. After gently equilibrating, selected microemulsions for 5 min were magnetic stirred. To check physical stability for ideal microemulsion, fresh and aged microemulsion formulations were tested by applying centrifugation test. The microemulsions were subjected to centrifugation at 5.175*g* for 30 min and observed for any phase separation ([@b0245], [@b0260]).

2.3. Preparation of FA loaded microemulsion based gel {#s0025}
-----------------------------------------------------

In [Table 1](#t0005){ref-type="table"}, the list of the materials that were used for preparing formulations in the present work, together with their abbreviations is provided. For preparing microemulsion based gel (MBG) COL (1%) was added to the water phase of the microemulsion.Table 1Components concentration (%) of the prepared microemulsion (M) and microemulsion-based gel formulations (MBG).Component (%)MMBGEO14.5814.58Tween 8053.7553.75EtOH8.9588.958Water22.7122.71 (1% COL)Surfactant/Cosurfactant ratio6:16:1

2.4. Characterization of formulations {#s0030}
-------------------------------------

In order to detect the suitability of formulations for topical administration, formulations were evaluated for their characteristic features such as pH, viscosity, droplet size, polydispersity index (PDI), zeta potential, drug content and spreadability.

### 2.4.1. Droplet size, PDI and zeta potential analysis {#s0035}

Dynamic Light Scattering method (Nano ZS, Malvern Instruments, U.K.) was used to measure the average droplet size and PDI. Experiments were repeated six times at 25 ± 1 °C. In order to measure the zeta potential of samples, capillary zeta cells were used. By using the Helmholtz--Smoluchowski equation, the zeta potential was detected. Software involved system was used for the process. The experiments were repeated six times at 25 ± 1 °C ([@b0240]).

### 2.4.2. Viscosity {#s0040}

Brookfield viscometer LVDV-E model was used to determine the viscosity of the formulations. The preparations were placed in the sampler tube. The formulations were measured with 50 rpm at 25 ± 0.5 °C.

### 2.4.3. Determination of pH {#s0045}

The pH of the formulations was detected using a calibrated pH meter (Mettler Toledo, Switzerland). Determinations were carried out four times.

### 2.4.4. Drug content {#s0050}

To determine drug content in the prepared formulations, the drug loaded formulations were dissolved in methanol and investigated with HPLC.

#### 2.4.4.1. HPLC studies {#s0055}

The mobile phase was prepared by mixing acetonitrile and ultrapure water (80:20) (v/v) with a flow rate of 1.7 mL/min. The flow rate was 1.7 mL/min and the column temperature was maintained at 25 ± 1 °C at 285 nm. The volume of injection was adjusted 20 μL. The run time was set at 10 min with the system operating at 25 ± 1 °C. The HPLC method was validated for linearity, the limit of detection and quantitation, precision, accuracy and specificity, selectivity and stability ([@b0265]).

### 2.4.5. Spreadability {#s0060}

To determine spreadability of formulations, 100 mg of blank and FA loaded formulations were transferred to the center of a glass plate at 32 °C. This plate was compressed under another plate. After one minute, the weight was removed and the diameter of the spread area (cm) was measured.

### 2.4.6. Stability of FA loaded microemulsion based gel {#s0065}

In physical stability studies, the formulation (FA-MBG) was placed at 4 ± 0.5 °C in the refrigerator and 25 ± 1 °C (relative humidity 60%) in the stability cabinets (Nuve, Turkey) for three months. After three months; visual appearance, clarity, pH, spreadability of the gel and FA content were determined.

2.5. *In vitro* drug release studies {#s0070}
------------------------------------

*In vitro* release experiment of microemulsion based gel formulation was performed in ethanol and PBS pH 7.4 (ratio of 30:70) at 50 rpm at 32 ± 0.5 °C. 5000 mg of FA-MBG was separated from release media by means of dialysis membrane (Spectra/por, MW of 12--14 kDa). 1 mL of sample was withdrawn at a predetermined time interval of 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 and 24 h. The samples were analyzed with HPLC. The experiment was repeated three times.

2.6. Microbiological studies of FA loaded microemulsion based gel {#s0075}
-----------------------------------------------------------------

### 2.6.1. Sterility studies {#s0080}

FA loaded MBG were prepared at Laminar air flow Cabinet (Haier HR40-IIA2). Sterility testing of the formulation was carried out under aseptic conditions. To check the sterility of the blank and FA loaded MBG sterility control testing was performed according to the international Pharmacopoeia (*The International Pharmacopoeia Fourth Edition*) and similar to the previously reported method ([@b0280]). For anaerobic bacteria, the Fluid thioglycollate medium was used. 1 mL of the formulation was added to each medium and incubated in BINDER GmbH incubator at 35 °C for bacteria and 25 °C for fungi for two weeks. No growth of the microorganisms occurred. For growth promotion test of aerobes, anaerboes and fungi, fluid thioglycollate media (using a separate portion of media for each microorganism) were inoculated with 100 CFU of *Staphylococcus aureus* ATCC 6538, *Clostridium sporogenes* ATCC 19404 and *Candida albicans* ATCC 10231. Media were incubated at 35 °C for 48 h.

### 2.6.2. Disk diffusion testing {#s0085}

The antibacterial effect of the microemulsion based gels both with FA and without FA and the commercial product (Fucidin 2%, Abdi İbrahim) was tested on *S. aureus* (ATCC 6538), *Bacillus cereus* (ATCC 7064), *Escherichia coli* (ATCC 8739), *Pseudomonas aeruginosa* (ATCC 27853), using both agar well diffusion method according to the guidelines of Clinical and Laboratory Standards Institute (standard M02-A) and previously reported methods ([@b0205]). Staphylococci are known to induce skin abscesses and worldwide they are the most commonly identified agent responsible for skin and soft tissue infections ([@b0090], [@b0210], [@b0270]). Gram negative *P. aeruginosa* is also known to be a common and increasing reason of skin infections that can result in potentially life-threatening septicemia ([@b0210], [@b0215]).

Bacteria were incubated on Nutrient Agar at 37 °C for 18 h. Active cultures were aseptically suspended in sterile saline and were arranged to give an inoculum with an equivalent cell density to 0.5 McFarland turbidity standard. 100 µL of each sample was spread evenly onto Mueller-Hinton II Agar and allowed to dry, and wells (diameter = 10 mm) were filled with 100 µL of formulations. They were stored at 37 ± 1 °C for 24--48 h and the inhibition diameters of each formulation for each isolate were detected by a digital ruler. Each test was completed in triplicate and the mean zone size was detected.

2.7. Anti-inflammatory activity {#s0090}
-------------------------------

### 2.7.1. Cell culture {#s0095}

The murine macrophage cell line RAW 264.7 was obtained from *American Type Culture Collection,* USA (ATCC). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco, NY, USA) supplemented with 10% heat-inactivated FBS and 1% penicillin (10.000 units/mL) and streptomycin (10.000 µg/ mL) in a humidified atmosphere of 5% CO~2~ at 37 °C. The effect of MBG and FA-MBG on cell viability, MTT colorimetric assay was used. Briefly, RAW 264.7 cells were plated at a density of 1 × 10^6^/mL and incubated for 24 h at 37 °C in 5% CO~2~. After 24 h, cells were treated with MBG and FA-MBG (0.025%, 0.05, %, 0.1%, 0.2%). After 24 h of incubation, the cell culture medium was discarded and MTT solution (0.5 mg/mL) was added to each well for an additional 2 h at 37 °C. After 2 h incubation, the cell culture medium was discarded and 100 μL of isopropanol was added to wells to dissolve formazan crystals. The optical density was measured at 570 nm wavelengths using an ELISA microplate reader (Thermo Multiskan Spectrum, Finland) ([@b0160]). The percentage of cell viability was detected by using the following equation:$$\mathit{Viability}\% = \left( {\mathit{Absorbanc}e_{\mathit{treatment}\mspace{6mu} group}} \right)/\left( {\mathit{Absorbanc}e_{\mathit{control}}} \right) \times 100\%.$$

### 2.7.2. Evaluation of anti-inflammatory activity by Griess assay {#s0100}

To determine the anti-inflammatory activity of the MBG and FA-MBG on RAW 264.7 cells, the Griess assay was performed ([@b0160]). Briefly, RAW 264.7 cells plated in a 48 well-plate at a density of 1 × 10^6^/mL and incubated for 24 h at 37 °C in 5% CO~2~. After 24 h of incubation, plated cells were pre-treated with MBG and FA-MBG (0.025%, 0.05%, 0.1%, 0.2%) for 2 h and then stimulated with 1 µg/mL of LPS (lipopolysaccharide from Escherichia coli 0111:B4, Sigma, USA) for additional 22 h. After total 24 h, 50 µL of cell culture supernatant was mixed with 50 µL Griess reagent in a 96-well plate (1% sulfanilamide and 0.1% N-(1-naphthyl) ethylenediamine dihydrochloride in 5% phosphoric acid) for 10 min in the dark at room temperature. The optical density was measured by using a microplate reader (Multiskan Ascent, Finland) at 540 nm wavelengths. The nitrite levels were determined by using sodium nitrite standard calibration curve. Indomethacin (100 µM) was used as a positive control.

### 2.7.3. Statistical analysis {#s0105}

All repeated experiments were conducted in triplicate. Statistical analysis of the results was performed by using GraphPad Prism 6 (Version 6.01; GraphPad Software, Inc., San Diego, CA). Differences between groups were analyzed by using one-way ANOVA following the post-hoc tests by Tukey. Group differences were considered to be significant at p \< 0.05(\*), p \< 0.01 (\*\*), p \< 0.001 (\*\*\*).

2.8. In vivo studies {#s0110}
--------------------

### 2.8.1. Animals {#s0115}

All animal studies were performed according to the Declaration of Helsinki and approved by the Local Animal Ethical Committee (Approval number: 38828770-604.01.01-E.46499). Male Wistar albino rats weighing 250 ± 10 g were purchased from the Experimental Animal Center of Istanbul Medipol University for the animal experiment. Rats were housed in a room maintained at 22 ± 1 °C with an alternating 12-h light/dark cycle. Animals had free access to a pellet diet and water ad libitum. The rats were transported to a quiet laboratory at least 1 h before the experiment began. For the *in vivo* studies, all studies were done between 09:00 to 12:00 a.m. under the normal room light and temperature (22 ± 1 °C).

### 2.8.2. Experimental groups and burn model {#s0120}

21 animals were divided into 3 groups (n = 7) each as follows;(1)Control group (Untreated group): CG(2)Fusidic acid (2%) loaded microemulsion based (FA-MBG) gel group: MG(3)Fucidin® (2% Fusidic acid) cream group (commercial product of FA): RG

All rats were anesthetized with ketamine (10 mg/kg)-xylazine (80 mg/kg) and the back of each animal was depilated and washed with the solution of povidone-iodine. The 2nd degree burn wounds (two full-thickness burn wounds per rat) were induced on the surgical area by using a temperature controlled modified heating instrument. The heated template (1 cm diameter) was applied perpendicularly to the designated area with gravitational pressure and temperature of 100 °C for 15 s ([@b0155]). The standard drug and the formulations (0.5 g) were topically applied once a day for 10 days.

### 2.8.3. Burned wound area measurement {#s0125}

Each burned wound site pictures were obtained with a camera (Canon, Japan) at days 0, 3, 5, 7, and 10 to measure wound contraction. The wounds photographs were performed at a 90° angle. An image analyser (Image J.2.0 software, NIH, USA) was used to detect wound surface areas during healing. The wound closure % was detected as follows:% Wound contraction = (Current wound area/wound area at the beginning) × 100 ([@b0145]).

### 2.8.4. Histology {#s0130}

The animals were sacrificed and the wound tissues were removed on day 10. The samples were fixed in 10% formalin, for one day and then embedded in paraffin, sever to 5 μm-thick portions, and dyed with Hematoxylin & Eosine for scoring under light microscopy. The histologic score system ranged between 1 and 4. Wound healing for each group was evaluated using the scoring system for epidermal and dermal regeneration described by [@b9000], ([@b0010]).

### 2.8.5. Statistical analysis {#s0135}

GraphPad Prism 7.0 was used for statistical analyses and graphs. The results were expressed as means ± standard error of the mean (SEM). Significant differences between groups were determined by one-way ANOVA using a Kruskal--Wallis test. Values for p \< 0.05 were considered statistically significant.

3. Results and discussion {#s0140}
=========================

A burn is a common medico-surgical problem all over the world. It is probably the most devastating of all wounds ([@b0045]). The imbalance between the pathological factors and integrity of immune defense mechanism promotes colonization of both gram-positive and gram-negative bacteria on the burning surface including *P. aeruginosa*, *S. aureus* and Methicillin-resistant *S. Aureus* ([@b0190], [@b0270])*.* Owing to the high amount of antimicrobial on the lesion surface, ease of rapid delivery, better adherence and decreased systemic toxicity risk, topical-antimicrobial therapy has always been considered advantageous ([@b0110]). However, creams and ointments fail to remain adhered to the lesion site and lose their rheological properties as they come in contact with the lesion fluid. This brings impaired drug delivery and increased applications of antibiotic ([@b0230]).

FA is the only fusidane-type antibiotic that has been clinically used. It has been applied to treat infections caused by methicillin resistant *Staphylococcus aureus* strains, and it is also effective against other species of Gram-positive bacteria FA blocks the translation elongation factor G gene in bacteria. Translation EF-G interacts consecutively with the ribosome during polypeptide synthesis ([@b0170]). The conventional topical formulations of FA fail to penetrate across the wound eschar leading to sub-optimal therapeutic efficacy and moreover, it has to be applied 2--3 times daily ([@b0175]).

In addition, some anti-bacterial agents (the nephro/hepatotoxicity of silver, argyria and dyschromia) for burned wounds, are not so advantageous as it is believed. Moreover, conventional wound dressings have several limitations including adherence to wound, resulting in ischemia and/or necrosis, the occurrence of a foreign-body reaction, and irritation, or allergic reaction ([@b0155]). Thus, the development of novel dressings with significant properties is mandatory.

3.1. Preparation and characterization of FA loaded microemulsion based gel {#s0145}
--------------------------------------------------------------------------

[Fig. 1](#f0005){ref-type="fig"} shows pseudo-ternary phase diagram of microemulsion composed of EO, tween 80, ethanol and distilled water. The construction of phase diagrams was used to detect the concentration range of components in the presence of microemulsion. The blank microemulsion was selected from the gravity center of the phase diagram. The surfactant/co-surfactant ratio with the highest area was determined as 6:1. The area of M1 microemulsion was determined as 862.04. It should be claimed that this phase diagram was obtained by maintaining the surfactant/co-surfactant ratio at 6:1. Hydrophilic lipophilic balance (HLB) value was determined as 12.077. After FA was dissolved in the system, the clear system was detected with no phase separation. The microemulsions had isotropic transparent dispersions and after centrifugation, no phase separation was observed. This demonstrated the good physical stability of the tested microemulsions.Fig. 1Pseudo-ternary phase diagrams of microemulsion composed of EO, Tween 80: Ethanol ratio 6:1 and distilled water.

Nonionic surfactants are known to be less toxic than ionic surfactants. In this study, tween 80 was used as a nonionic surfactant. Surfactants with high HLB (\>12) values assist the immediate formation of o/w droplet and rapid spreading of the formation in aqueous media ([@b0220]). Ethanol was applied as cosurfactant. Short to medium chain length alcohols are generally added as co-surfactants to increase the fluidity of interface ([@b0225]).

Microemulsion-based gel was successfully prepared with COL (1%) as a gelling agent to impart viscosity to the preparation as well as to sustain the action of the drug by increasing residence time. Polysaccharides have been considered to encourage wound healing which is quite important for the development of effective and non-toxic drugs with better activities *in vitro* and *in vivo* ([@b0235]).

Physicochemical characterization of microemulsion formulations especially for dermal application is an important subject to be considered during the formulation development phase ([@b0255]). The physicochemical characterization parameters of blank microemulsion (M), FA loaded microemulsion (FA-M), blank microemulsion based gel (MBG) and FA loaded microemulsion based gel (FA-MBG) is reported in [Table 2](#t0010){ref-type="table"}. The droplet size of M and FA-M ranged from 9.39 to 11.22 nm with low PDI values. On the other hand, the droplet size of MBG and FA-MBG ranged from 20.56 to 21.27 nm with low PDI values. It can be said that FA entrapment increased the droplet size. Similar results have been reported for rosiglitazone-loaded cationic lipid emulsion ([@b0040]). A near-neutral surface charge was observed for M and FA-M formulations. Zeta potential of MBG and FA-MBG was found as 15.8 ± 1.03 and 14.69 ± 0.92 mV, respectively. Spreadability test was carried out for all the formulations since it is important for patient compliance and helps in the uniform application of gel to the skin ([@b0200]). Spreadability values of the MBG and FA-MBG were decreased compared to microemulsion spreadability which could be associated with COL addition. The pH values of formulations ranged from 5 to 5.41, are close to the pH values of normal skin. This fact can imply formulations compatibility with skin. The viscosity of MBG was significantly higher than that of M (1523.33 ± 2 cP vs 692.53 ± 1.25 cP). It can be claimed that the increase of viscosity was due to the addition of COL, since gelling agents such as chitosan can increase the viscosity of formulations. This enhanced viscosity improves the suitability of formulations for topical administration ([@b0280]). Finally, the drug content uniformity of FA-M and FA-MBG was found to be 95.42 ± 3.07, 95.36 ± 4.15, respectively. Similar drug content results also revealed by Mali et al., where microemulsions loaded with lipophilic itraconazole were studied ([@b0115]). Besides, microemulsions and microemulsions based gels are chosen for topical administration systems due to their enhanced drug entrapment and their ability to solubilize the lipophilic drug moiety which shows rapid and efficient penetration to the skin ([@b0120]).Table 2Characterization results of blank and FA loaded microemulsion and microemulsion based gel fomulations.Formulation codepHViscosity (cP)Droplet size (nm)PDIZeta potentialSpreadability (cm)Drug content (%)M5 ± 0.06692.53 ± 1.2511.22 ± 0.220.45 ± 0.08−1.45 ± 0.364.5 ± 0.05--MBG5.41 ± 0.051523.33 ± 220.56 ± 0.370.312 ± 0.0115.8 ± 1.033.28 ± 0.18--FA-M5.04 ± 0.02410.43 ± 0.759.39 ± 0.290.47 ± 0.1−1.05 ± 0.545.35 ± 0.3095.42 ± 3.07FA-MBG5.07 ± 0.021468.33 ± 2.721.27 ± 0.195.0.308 ± 0.0314.69 ± 0.923.07 ± 0.1295.36 ± 4.15

Due to the above characterization results, as optimal dermal carrier was chosen FA-MBG and thus it was further studied in context of stability and *in vitro* release. In later stages, antimicrobial activity and healing properties were also evaluated for the chosen desirable carrier.

3.2. Stability studies of FA loaded microemulsion based gel {#s0150}
-----------------------------------------------------------

The stability experiments were performed at 4 ± 1 °C and 25 ± 1 °C, for a period of 3 months. [Table 3](#t0015){ref-type="table"} shows stability studies results of FA-MBG formulation. There was no significant change in clarity, pH and drug content of the FA-MBG after 3 months of stability testing. Thus, the prepared FA-MBG can be declared as stable at 4 °C and room temperature for 3 months.Table 3Stability studies of FA-MBG formulation.Parameterst = 0 monthst = 3 months4 ± 0.5 °C/25 ± 1 °C4 ± 0.5 °C25 ± 1 °CpH4.47 ± 0.025.117 ± 0.0125.053 ± 0.015Spreadability (cm)3.07 ± 0.121.850 ± 0.0711.875 ± 0.035Drug content (%)95.36 ± 4.1595.070 ± 2.44594.053 ± 1.477

3.3. *In vitro* drug release study of FA loaded microemulsion based gel {#s0155}
-----------------------------------------------------------------------

*In vitro* drug release of the microemulsion was evaluated via dialysis bag technique, using pH 7.4 as release medium. [Fig. 2](#f0010){ref-type="fig"} depicts *in vitro* drug release results of FA-MBG. It is well reported that FA is not soluble in water, so a very low dissolution rate has been reported in pH = 7.4. First of all, it can be indicated that prolonged- controlled release pattern with 10% burst effect was achieved. Nonetheless, improved gradual release of FA for 24 h is seen. Finally, maximum drug release from microemulsion based gel was achieved within 24 h. Similarly, numerous studies can be found which exhibit that lipophilic drug loaded microemulsions showed prolonged release ([@b0055], [@b0150], [@b0275]).Fig. 2*In vitro* drug release results of FA-MBG (n:3, ±STD).

3.4. Microbiological studies of FA loaded microemulsion based gel {#s0160}
-----------------------------------------------------------------

Wound infection is a big problem in burn therapy since it is the most prevalent reason of mortality ([@b0030], [@b0125], [@b0140]). Pathogens have evolved over time in line with antibiotic use ([@b0285]). With limited new antibiotics, discoveries increasing the efficacy of currently available antimicrobials is remarkable to enhance morbidity in burn sufferer ([@b0100]). Infection not only could have serious threats on patient's life, but it also delays the healing process resulting in prolonged hospitalization time and cost ([@b0155], [@b0210]). Burns are particularly susceptible to infection for several reasons. The disruption of the epidermal barrier combined with the denaturation of proteins and lipids provides a fertile environment for microbial growth ([@b0195]). From the results of the sterility studies of the formulations with FA, it was demonstrated that no growth of any of the inoculated microorganisms occurred after the incubation period. Moreover, it can be reported that the prepared microemulsion based gel showed an antibacterial effect on the selected microorganisms. [Fig. 3](#f0015){ref-type="fig"} shows zone inhibition diameters of FA-MBG, MBG and commercial product of FA. Blank MBG (not containing FA) as it was expected did not show any inhibition zones on *E. coli* and *P. aeruginosa*, which are both gram negative bacteria. In gram positive bacteria (*S. aureus* and *B. cereus*) there was a minor inhibition zone, probably due to COL addition. It is well known, that chitosan possesses antimicrobial activity against some strains ([@b0210]). The microemulsion based hydrogel showed greater inhibition zone diameters for all the bacteria except *P. aeruginosa* compared to the commercial product ([Table 4](#t0020){ref-type="table"}). According to our results, while *P. aeruginosa* and *E. coli* showed the narrowest inhibition zone, the largest zone was observed in *S. aureus*, which is the most reported bacterium that causes infections on soft tissues.Fig. 3Zone inhibition diameters of FA-MBG, MBG and commercial product of FA.Table 4Microbiological studies results of formulations with FA (FA-MBG), without FA (MBG) and commercial product of FA.FA-MBG (mm)MBG (mm)Commercial product (mm)*E. coli*17--170--010--9*S. aureus*50--5119--1847--49*P. aeruginosa*20--200--040--40.5*B. cereus*30--2916--1624--24

3.5. Anti-inflammatory activity {#s0165}
-------------------------------

Before analyzing the potential anti-inflammatory activity of the MBG and FA-MBG by measuring nitrite levels in cell culture medium, non-toxic concentrations with viability more than 70% were determined. Therefore, cytotoxic effects of MBG and FA-MBG were examined on RAW 264.7 murine macrophage cells by MTT colorimetric assay after 24 h of treatment with varying concentrations (0.025%, 0.05%, 0.1%, 0.2%) of MBG and FA-MBG. [Fig. 4](#f0020){ref-type="fig"} shows effect of MBG and FA-MBG on RAW 264.7 cell viability. It can be concluded that viability is high and acceptable for such formulations. These results are rational given that the used chemical substances are non-toxic.Fig. 4Effects of MBG and FA-MBG (0.025%, 0.05%, 0.1%, 0.2%) on RAW 264.7 cell viability. Cells were treated with indicated concentrations of MBG and FA-MBG for 24 h and then cell viability was assessed by MTT assay. Untreated cells taken as 100% viability.

### 3.5.1. Nitric oxide production in Lps-stimulated RAW 264.7 cells {#s0170}

Nitric oxide (NO) is well known to be one of the major regulators of wound healing. However, excessive NO production was demonstrated to play a critical role in the pathogenesis of inflammation and can lead to cellular death and tissue damage in high amounts by reacting with reactive oxygen species ([@b0180]). Therefore, inhibition of NO production is an important strategy for the screening of anti-inflammatory formulation.

In the present study, both of the formulations, MBG and FA-MBG exert anti-inflammatory effects in LPS induced RAW 264.7 macrophage dose dependent manner. The effects of MBG and FA-MBG on NO production were assessed by Griess assay by evaluating the decrease in nitrite production levels *in vitro*. As in [Fig. 5](#f0025){ref-type="fig"}, MBG and FA-MBG decreased nitrite levels by up to 80% in LPS-stimulated RAW 264.7 cells and showed the strongest anti-inflammatory affect at the highest dose administered (0.2%).Fig.5Effects of MBG and FA-MBG (0.025%, 0.05%, 0.1%, 0.2%) on the nitrite production in 1 µg/mL LPS-induced RAW 264.7 cells.

3.6. In vivo studies {#s0175}
--------------------

### 3.6.1. Macroscopic burn healing {#s0180}

In this study, the burn healing potential was evaluated through 10 days experimental period by monitoring regularly the percentage of wound areas contraction. Experimental 2nd degree burns were created on the backs of rats and all lesions were treated for 10 days to investigate the burn healing activity of FA loaded microemulsion based gel group (MG). The degree of a burn injury can be classified into first, second, third, or fourth degree burns according to the depth of tissue injury. 2nd degree burns can affect either papillary layer (i.e. the upper dermis) or reticular layer (i.e. the deeper dermis) with white or yellow color, blistering of the skin, and a moist appearance ([@b0130]).

The daily behaviors (food intake, activity, e.g.) of rats were observed as normal. The macroscopic photos of the burn areas on days 0, 3, 5, 7 and 10 were presented in [Fig. 6](#f0030){ref-type="fig"}. On day 1, necrosis and edema were observed on the wound surface areas in all groups. Exudates were also seen, and the edges of the wounds started to pronounce. Edema was also present around the wound surface area. Crust formations were observed on the skin after several days. It was found out that MG treatment did not get irritated the skin. Furthermore, on the 10th day, the crust layer of MG was fell off.Fig. 6Effects of MG on wound's evolution. Macroscopic examples of wound healing with control (CG), MG, and Fucidin® (RG) groups after excision on days 0, 3, 5, 7, and 10.

The wound contraction ratio was assessed as the percentage reducing in wound size on days 0, 3, 5, 7, and 10. As it is illustrated in [Fig. 7](#f0035){ref-type="fig"}, MG showed a significant burn healing progression on the day 3 (P \< 0.01), 5 (P \< 0.01), 7 (P \< 0.01), and 10 (P \< 0.01) compared to untreated group. The healing percent of lesion area ranged from 90.11% to 65.49% in the period from 3 to 10 days in the control group (CG). The % of the burn area treated with RG ranged from 77.29% to 46.71% in the period from 3 to 10 days. The % of wound area in rats treated with MG ranged from 69.30% to 41.39% in the period from 3 to 10 days. Compared to the control group, MG and RG recovered quickly and the burn area rapidly decreased in size by the tenth day. The main objective in burn injury healing is the early wound closure and rapid replacement of normal skin with minimal scarring ([@b0085], [@b0130]).Fig. 7The rate of wound healing of scar tissue surface area in animal groups on days 0--10. Each data point represents the mean ± SEM.

### 3.6.2. Histology of wound healing {#s0185}

Histopathological analysis showed differences in the healing phase of the control group and the groups. Wound healing is a complex and continuous process, but for descriptive purposes, it is divided into 3 biologically distinct, although overlapping stages; the inflammatory, the repair or proliferative, and the remodeling stage ([@b0145]). ﻿Extensive tissue damaged during burns impairs angiogenesis, collagen re-organization, granulation tissue formation and induces free radical-mediated damage which results in delayed tissue repair ([@b0080]). From the 3rd day, a proliferative phase has been triggered and characterized by the formation of granulation tissue, including angiogenesis, the migration of fibroblasts, and collagen synthesis ([@b0185]).

The microscopic photos were taken during the histological examination of the wound tissues on the 10th day are given in [Fig. 8](#f0040){ref-type="fig"}. Histopathological examination of wound tissues on the 10th day is illustrated in [Fig. 9](#f0045){ref-type="fig"}.Fig. 8Histopathological view of scarred tissues of the control (CG), FA (2%) loaded MBG gel (MG), and Fucidin® (RG) groups on the 10th day after the burning process (Hematoxylin and eosin (H&E) (original magnificationX10). The scale bars represent 100 μm for the figure.Fig. 9Microscopic investigation of granulation tissue thickness, angiogenesis and epidermal-dermal regeneration on control (CG), FA (2%) loaded MBG gel (MG), and Fucidin® (RG) groups by histological wound healing scores among. Statistically significant as compared to control; P \< 0.05(\*), P \< 0.01(^\*\*^).

In the present study, hematoxylin and eosin stained sections of wound tissues were used to evaluate re-epithelization, revascularization and organization of granulation tissue.

As stated in the obtained outcomes, it was determined that MG and RG had a significant effect compared to the control group ([Fig. 8](#f0040){ref-type="fig"}, [Fig. 9](#f0045){ref-type="fig"}).

It has been shown that there were significantly higher percentages of dermal and epidermal regeneration with the MG (P \< 0.05) and PG (P \< 0.05) in comparison to the untreated group ([Fig. 8](#f0040){ref-type="fig"}, [Fig. 9](#f0045){ref-type="fig"}). Re-epithelialization is induced by activation of cytokines and growth factors which cause expansion of keratinocytes, epithelial cells, stem cells and fibroblasts ([@b0130]).

According to the histological evaluation results, more blood vessel formation was detected on MG (P \< 0.05) and RG (P \< 0.05) in comparison to the untreated group. Angiogenesis phase, several growth factors and thrombin, which are the foremost activating molecules for endothelial cell growth ([@b0130]).

Moreover, it was seen that thicker granulation tissue was formed in the MG (P \< 0.01) in comparison to the untreated group after treatment ([Fig. 8](#f0040){ref-type="fig"}, [Fig. 9](#f0045){ref-type="fig"}). Also, MG provides new granulation tissue formation more than RG (P \< 0.05) ([Fig. 8](#f0040){ref-type="fig"}, [Fig. 9](#f0045){ref-type="fig"}). The final step of the proliferation phase is the production of granulation tissue, which can be specified by the presence of many fibroblasts, granulocytes and macrophages ([@b0130]).

4. Conclusıon {#s0190}
=============

In this work, the potential of FA loaded MBG as drug carriers for dermal delivery was evaluated. The findings indicated that MBG formulation exhibited significant antibacterial properties. This result provided support for the promising use of FA for applications as a therapeutic agent for dermal wound healing. The developed system demonstrated improved wound healing, good spreadability and enhanced therapeutic efficacy given that at the end of the 10th day of *in vivo* experiment, the healing percent of lesion area was found as 46.71% for commercial product and 41.39% for FA-MBG. In conclusion, the present study can open up a window for dermal application of MBG loaded with FA, and it would be a better alternative to conventional dermal creams in burn healing.
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